MétaCan
Menu
Back to cohort
Record W2954903295 · doi:10.1055/s-0039-1693256

Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus Hospitalizations among Infants Born at 33 to 35 Weeks Gestational Age in the Province of Quebec, Canada (RSV-QC Study)

2019· article· en· W2954903295 on OpenAlexaffabout
Jesse Papenburg, Isabelle Defoy, Édith Massé, Georges Caouette, Marc Lebel

Bibliographic record

VenueAmerican Journal of Perinatology · 2019
Typearticle
Languageen
FieldMedicine
TopicRespiratory viral infections research
Canadian institutionsUniversité de MontréalCentre Hospitalier Universitaire Sainte-JustineCentre hospitalier universitaire de QuébecCentre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-JeanABB (Canada)Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-MontréalCentre Hospitalier Universitaire de SherbrookeMcGill University Health Centre
Fundersnot available
KeywordsPalivizumabMedicineGestational ageIncidence (geometry)PediatricsRespiratory systemGestationVirusPneumovirinaePregnancyParamyxoviridaeViral diseaseVirologyInternal medicine

Abstract

fetched live from OpenAlex

Introduction: In the Province of Quebec, until 2014 to 2015, infants <6 months of age born at 33 to 35 weeks gestational age (wGA) and classified as moderate to high risk by a Canadian risk scoring tool were included in a palivizumab (PZB) respiratory syncytial virus (RSV) prophylaxis program. We assessed the impact of withdrawal of this indication since 2015 to 2016. Materials and Methods: We conducted a 4-year observational study in 25 Quebec hospitals. Births at 33 to 35 wGA and lower respiratory tract infection (LRTI)/RSV hospitalizations (H) were identified via discharge databases using International Classification of Diseases-9 or -10 codes. Subjects with other indications for PZB were excluded. Our primary outcome was LRTI/RSV-H, defined as LRTI with laboratory-confirmed RSV or LRTI not virologically tested during RSV season (November–April). Using multivariable regression analyses, we compared the risk of LRTI/RSV-H before (2013–2015; S1/2) and after (2015–2017; S3/4) the change in recommendations. Through chart review and mailed parental questionnaire, we described the clinical course and caregiver burden (health resource utilization; productivity; stressors) of LRTI/RSV-H in 33 to 35 wGA infants. Results: We identified 6,457 eligible 33 to 35 wGA births in 4 years. LRTI/RSV-H occurred in 105/3,353 (3.13%) infants in S1/2 compared with 130/3,104 (4.19%) in S3/4. Overall, 86.4% were RSV confirmed. In multivariable logistic regression analysis adjusting for sex, wGA, and birth month, S3/4 was significantly associated with LRTI/RSV-H (odds ratio [OR]: 1.36, 95% confidence interval [CI]: 1.04–1.76) but not with RSV-confirmed hospitalization (OR: 1.19, 95% CI: 0.90–1.58). Mean hospital stay duration was 5.6 days; 22.6% required intensive care unit admission and 11.1% mechanical ventilation (mean duration 5.4 days). Prior to admission, subjects had an average of 2.3 emergency room and 2.1 clinic visits for their LRTI. Fathers reported a mean of 28.5 hours missed work because of the hospitalization. Comparing S3/4 to S1/2, the proportion of infants with LRTI/RSV-H classified as moderate to high risk increased from 27.7 to 42.0%. Conclusion: In a province-wide study, we observed an increase in LRTI/RSV-H among 33 to 35 wGA infants in 2 years after withdrawal of PZB prophylaxis, associated with important, increased health care utilization and parental burden. Conflict of Interest: G.C. has no conflict of interest or any ongoing financial, professional, or personal relationships with AbbVie except an unrestricted grant for this study and consulting honorarium for the study from AbbVie. M.L. has received an unrestricted grant from AbbVie for this study. E.M. has no bias, affiliation with AbbVie or disclosure to declare; received an unrestricted grant for this study. J.P. has received consulting/speaker fees/honoraria from AbbVie, BD Diagnostics, Cepheid; and research grant funding and contracted research from AbbVie, MedImmune, Janssen, BD Diagnostics. I.D. is an AbbVie employee and holds stock or stock options AbbVie. Funding: AbbVie Inc. funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.022
Threshold uncertainty score0.162

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.005
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0000.001
Science and technology studies0.0010.001
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.010
GPT teacher head0.312
Teacher spread0.302 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2019
Admission routes2
Has abstractyes

Explore more

Same venueAmerican Journal of PerinatologySame topicRespiratory viral infections researchFrench-language works237,207